An analysis of granulation patterns, MIB-1 proliferation indices and p53 expression in 101 patients with acromegaly

Acta Neurochirurgica

Volumn 156, Issue 12, 2014, Pages 2221-2230

  Sarkar, Sauradeep ^a   Chacko, Ari George ^a   Chacko, Geeta ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

Acromegaly; Densely granulated adenomas; Growth hormone; MIB 1 index; Sparsely granulated adenoma

Indexed keywords

CABERGOLINE; CYTOKERATIN; GROWTH HORMONE; KI 67 ANTIGEN; PROLACTIN; PROTEIN P53; SOMATOMEDIN C;

ACROMEGALY; ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROADENOMA; MINIMAL RESIDUAL DISEASE; MITOSIS RATE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEREOTACTIC RADIOSURGERY; TRANSSPHENOIDAL SURGERY; TUMOR INVASION; TUMOR REGRESSION; TUMOR VOLUME; ADENOMA; COMPLICATION; GENETICS; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; METABOLISM; MIDDLE AGED; MITOSIS INDEX; PATHOLOGY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ACROMEGALY; ADENOMA; ADULT; FEMALE; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; INSULIN-LIKE GROWTH FACTOR I; KI-67 ANTIGEN; MALE; MIDDLE AGED; MITOTIC INDEX; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84922004226     PISSN: 00016268     EISSN: 09420940     Source Type: Journal    
DOI: 10.1007/s00701-014-2230-6     Document Type: Article

References (47)

1. Albarel F, Castinetti F, Morange I, Conte‐Devolx B, Gaudart J, Dufour H, Brue T (2013) Outcome of multimodal therapy in operated acromegalic patients, a study in 115 patients. Clin Endocrinol (Oxf) 78:263–270
2. Bakhtiar Y, Hirano H, Arita K, Yunoue S, Fujio S, Tominaga A, Sakoguchi T, Sugiyama K, Kurisu K, Yasufuku-Takano J (2010) Relationship between cytokeratin staining patterns and clinico-pathological features in somatotropinomae. Eur J Endocrinol 163:531–539
3. Bando H, Sano T, Ohshima T, Zhang C, Yamasaki R, Matsumoto K, Saito S (1992) Differences in pathological findings and growth hormone responses in patients with growth hormone-producing pituitary adenoma. Endocrinol Jpn 39:355–363
4. Barkan AL, Stred SE, Reno K, Markovs M, Hopwood NJ, Kelch RP, Beitins IZ (1989) Increased growth hormone pulse frequency in acromegaly. J Clin Endocrinol Metab 69:1225–1233
5. Bianchi A, Giustina A, Cimino V, Pola R, Angelini F, Pontecorvi A, De Marinis L (2009) Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly. J Clin Endocrinol Metab 94:2015–2022
6. Botelho CHA, Magalhães AV, Mello PA, Schmitt FC, Casulari LA (2006) Expression of p53, Ki-67 and c-erb B2 in growth hormone-and/or prolactin-secreting pituitary adenomas. Arq Neuropsiquiatr 64:60–66
7. Chacko G, Chacko AG, Kovacs K, Scheithauer BW, Mani S, Muliyil J, Seshadri M (2010) The clinical significance of MIB-1 labeling index in pituitary adenomas. Pituitary 13:337–344
8. Cottier JP, Destrieux C, Brunereau L, Bertrand P, Moreau L, Jan M, Herbreteau D (2000) Cavernous sinus invasion by pituitary adenoma: MR imaging. Radiology 215:463–469
9. DeLellis R, Lloyd RV, Heitz P, Eng C (2004) World Health Organization classification of tumours: tumours of endocrine organs. IARC Press, Lyon
10. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG (1999) Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59:793–797
11. Fougner SL, Casar‐Borota O, Heck A, Berg JP, Bollerslev J (2012) Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clin Endocrinol (Oxf) 76:96–102
12. Fusco A, Zatelli M, Bianchi A, Cimino V, Tilaro L, Veltri F, Angelini F, Lauriola L, Vellone V, Doglietto F (2008) Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas. J Clin Endocrinol Metab 93:2746–2750
13. Hartman ML, Veldhuis JD, Vance ML, Faria AC, Furlanetto W, Thorner MO (1990) Somatotropin pulse frequency and basal concentrations are increased in acromegaly and are reduced by successful therapy. J Clin Endocrinol Metab 70:1375–1384
14. Hazer DB, Işık S, Berker D, Güler S, Gürlek A, Yücel T, Berker M (2013) Treatment of acromegaly by endoscopic transsphenoidal surgery: surgical experience in 214 cases and cure rates according to current consensus criteria: Clinical article. J Neurosurg 119:1467–1477
15. Hentschel SJ, McCutcheon IE, Moore W, Durity FA (2003) P53 and MIB-1 immunohistochemistry as predictors of the clinical behavior of nonfunctioning pituitary adenomas. Can J Neurol Sci 30:215–219
16. Hofstetter CP, Mannaa RH, Mubita L, Anand VK, Kennedy JW, Dehdashti AR, Schwartz TH (2010) Endoscopic endonasal transsphenoidal surgery for growth hormone-secreting pituitary adenomas. Neurosurg Focus 29:E6
17. Jaffrain-Rea M, Di Stefano D, Minniti G, Esposito V, Bultrini A, Ferretti E, Santoro A, Scucchi LF, Gulino A, Cantore G (2002) A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas. Endocr Relat Cancer 9:103–113
18. Kawamoto H, Uozumi T, Kawamoto K, Arita K, Yano T, Hirohata T (1995) Analysis of the growth rate and cavernous sinus invasion of pituitary adenomas. Acta Neurochir (Wien) 136:37–43
19. Kiseljak-Vassiliades K, Shafi S, Kerr JM, Phang TL, Kleinschmidt-DeMasters B, Wierman ME (2012) Clinical implications of growth hormone–secreting tumor subtypes. Endocrine 42:18–28
20. Kontogeorgos G, Sambaziotis D, Piaditis G, Karameris A (1997) Apoptosis in human pituitary adenomas: a morphologic and in situ end-labeling study. Mod Pathol 10:921–926
21. Kovacs K, Scheithauer BW, Lombardero M, McLendon RE, Syro LV, Uribe H, Ortiz LD, Penagos LC (2008) MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathol 115:261–262
22. Kreutzer J, Vance M, Lopes M, Laws E (2001) Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab 86:4072–4077
23. Leontiou CA, Gueorguiev M, van der Spuy J, Quinton R, Lolli F, Hassan S, Chahal HS, Igreja SC, Jordan S, Rowe J (2008) The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab 93:2390–2401
24. Lopes MBS (2010) Growth hormone-secreting adenomas: pathology and cell biology. Neurosurg Focus 29:E2
25. Losa M, Barzaghi RL, Mortini P, Franzin A, Mangili F, Terreni MR, Giovanelli M (2000) Determination of the proliferation and apoptotic index in adrenocorticotropin-secreting pituitary tumors: comparison between micro-and macroadenomas. Am J Pathol 156:245–251
26. Mantovani G, Lania A, Spada A (2010) GNAS imprinting and pituitary tumors. Mol Cell Endocrinol 326:15–18
27. Mastronardi L, Guiducci A, Spera C, Puzzilli F, Liberati F, Maira G (1999) Ki-67 labelling index and invasiveness among anterior pituitary adenomas: analysis of 103 cases using the MIB-1 monoclonal antibody. J Clin Pathol 52:107–111
28. Mayr B, Buslei R, Theodoropoulou M, Stalla GK, Buchfelder M, Schöfl C (2013) Molecular and functional properties of densely and sparsely granulated GH-producing pituitary adenomas. Eur J Endocrinol 169:391–400
29. Mazal P, Czech T, Sedivy R, Aichholzer M, Wanschitz J, Klupp N, Budka H (2001) Prognostic relevance of intracytoplasmic cytokeratin pattern, hormone expression profile, and cell proliferation in pituitary adenomas of akromegalic patients. Clin Neuropathol 20:163–171
30. McCormack AI, McDonald KL, Gill AJ, Clark SJ, Burt MG, Campbell KA, Braund WJ, Little NS, Cook RJ, Grossman AB (2009) Low O6‐methylguanine‐DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin Endocrinol (Oxf) 71:226–233
31. Mete O, Ezzat S, Asa SL (2012) Biomarkers of aggressive pituitary adenomas. J Mol Endocrinol 49:R69–R78
32. Nehru GA, Pai R, Samuel P, Chacko AG, Chacko G (2012) Status of O 6-methylguanine-DNA methyltransferase [MGMT] gene promoter methylation among patients with glioblastomas from India. Neurol India 60:481–486
33. Nyquist P, Laws ER Jr, Elliott E (1994) Novel features of tumors that secrete both growth hormone and prolactin in acromegaly. Neurosurgery 35:179–184
34. Obari A, Sano T, Ohyama K, Kudo E, Qian ZR, Yoneda A, Rayhan N, Rahman MM, Yamada S (2008) Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr Pathol 19:82–91
35. Osamura RY, Watanabe K (1987) Immunohistochemical colocalization of growth hormone (GH) and alpha subunit in human GH secreting pituitary adenomas. Virchows Arch A Pathol Anat Histopathol 411:323–30
36. Pan LX, Chen ZP, Liu YS, Zhao JH (2005) Magnetic resonance imaging and biological markers in pituitary adenomas with invasion of the cavernous sinus space. J Neurooncol 74:71–76
37. Sambaziotis D, Kapranos N, Kontogeorgos G (2003) Correlation of bcl-2 and bax with apoptosis in human pituitary adenomas. Pituitary 6:127–133
38. Sano T, Ohshima T, Yamada S (1991) Expression of glycoprotein hormones and intracytoplasmic distribution of cytokeratin in growth hormone-producing pituitary adenomas. Pathol Res Pract 187:530–533
39. Scheithauer BW, Gaffey TA, Lloyd RV, Sebo TJ, Kovacs KT, Horvath E, Yapcer Ö, Young WF Jr, Meyer FB, Kuroki T (2006) Pathobiology of pituitary adenomas and carcinomas. Neurosurgery 59:341–353
40. Shin SS, Tormenti MJ, Paluzzi A, Rothfus WE, Chang Y-F, Zainah H, Fernandez-Miranda JC, Snyderman CH, Challinor SM, Gardner PA (2012) Endoscopic endonasal approach for growth hormone secreting pituitary adenomas: outcomes in 53 patients using 2010 consensus criteria for remission. Pituitary 16:435–444
41. Spada A, Arosio M, Bochicchio D, Bazzoni N, Vallar L, Bassetti M, Faglia G (1990) Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase. J Clin Endocrinol Metab 71:1421–1426
42. Starke RM, Raper DM, Payne SC, Vance ML, Oldfield EH, Jane JA (2013) Endoscopic versus microsurgical transsphenoidal surgery for acromegaly: outcomes in a concurrent series of patients using modern criteria for remission. J Clin Endocrinol Metab 98:3190–3198
43. Suliman M, Royds J, Cullen D, Timperley W, Powell T, Battersby R, Jones TH (2001) Mdm2 and the p53 pathway in human pituitary adenomas. Clin Endocrinol (Oxf) 54:317–325
44. Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horvath E, Pernicone PJ, Murray D, Laws ER Jr (1996) Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38:99–107
45. Yamada S, Aiba T, Sano T, Kovacs K, Shishiba Y, Sawano S, Takada K (1993) Growth hormone-producing pituitary adenomas: correlations between clinical characteristics and morphology. Neurosurgery 33:20–27
46. Yonezawa MDK, Tamaki MDN, Kokunai MDT (1997) Clinical features and growth fractions of pituitary adenomas. Surg Neurol 48:494–500
47. Zada G, Woodmansee WW, Ramkissoon S, Amadio J, Nose V, Laws ER Jr (2011) Atypical pituitary adenomas: incidence, clinical characteristics, and implications: Clinical article. J Neurosurg 114:336–344